Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, July 22 - Friday, July 26, 2024), and click each link to read and watch anything you may have missed.
1.) FDA approves femlyv as the first orally disintegrating tablet for pregnancy prevention
Femlyv, containing norethindrone acetate and ethinyl estradiol, offers a new oral contraceptive option for individuals with swallowing difficulties, expanding access and convenience.
Click here for the full article.
2.) First patient dosed in RECONNECT trial of RE104 for postpartum depression
Reunion Neuroscience Inc. initiates phase 2 trial of RE104, a novel short-duration psychedelic treatment for postpartum depression, aiming to provide rapid and effective relief for affected mothers.
Click here for the full article.
3.) Unexpected RBC antibodies found in 1.85% of pregnant women
A recent study reveals that unexpected red blood cell antibodies are present in 1.85% of pregnant women, highlighting the need for potential interventions to manage fetal anemia.
Click here for the full article.
4.) ZY5301 tablet effective for chronic pelvic pain
These results indicated a significant reduction of CPP from 12 weeks of ZY5301 treatment. Investigators recommended a ZY5301 600 mg/d dose be investigated in a phase 3 trial.
Click here for the full article.
5.) ACOG release new practice update on biomarker testing for hypertensive disorders in pregnancy
Padmashree Woodham, MD, professor of maternal-fetal medicine at Wellstar Medical College of Georgia Health, outlines the new ACOG practice update on biomarker testing for risk assessment of hypertensive disorders in pregnancy.
Recap on reproductive rights with David Hackney, MD, MS
December 20th 2022In this episode of Pap Talk, we spoke with David Hackney, MD, MS, maternal-fetal medicine physician at Case Western Reserve University and chair of ACOG's Ohio chapter for a full recap of where restrictions on reproductive rights have been and where they're going.
Listen
Preference for alternative contraceptive sources reported by many patients
October 31st 2024With nearly half of short-acting contraceptive users preferring non-traditional sources such as telehealth and over-the-counter options, a recent study highlights evolving patient needs in contraceptive access.
Read More
In this episode of Pap Talk, Gloria Bachmann, MD, MSc, breaks down what it means to be a health care provider for incarcerated individuals, and explores the specific challenges women and their providers face during and after incarceration. Joined by sexual health expert Michael Krychman, MD, Bachmann also discusses trauma-informed care and how providers can get informed.
Listen
Increasing ondansetron use reported against NVP in the United States
October 29th 2024Despite being recommended as a third-line therapy, rates of ondansetron use to treat nausea and vomiting in pregnancy have increased, making it the most common prescription antiemetic against this condition in the United States.
Read More
HP-hMG stimulation reduces OHSS risk in high responder patients
October 25th 2024A recent study found that highly purified human menotropin significantly lowers the risk of ovarian hyperstimulation syndrome compared to recombinant follicle stimulating hormone, highlighting the benefits of protocol individualization based on gonadotropin type.
Read More